Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lifted its position in Pfizer Inc. (NYSE:PFE) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,939,029 shares of the biopharmaceutical company’s stock after purchasing an additional 46,366 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Pfizer were worth $48,282,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer during the 3rd quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the 2nd quarter valued at approximately $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $32,000. Finally, True Wealth Design LLC increased its stake in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on PFE shares. Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. Guggenheim lifted their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a report on Thursday, February 12th. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.19.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 TALAPRO-3 topline results for TALZENNA® (supports late‑stage oncology positioning), which bolsters Pfizer’s mid/late‑stage pipeline and revenue optionality. Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®
• Positive Sentiment: Encouraging oncology and immunology clinical updates (positive phase 2 atirmociclib in metastatic breast cancer; topline tilrekimig eczema data) and management’s plan for ~20 pivotal trial starts this year—supports the narrative that growth is shifting beyond legacy COVID revenues. Pfizer’s Oncology And Immunology Wins Shift Focus Beyond COVID Revenues
• Positive Sentiment: Market coverage noting Pfizer outperformed the broader market decline today, citing the above pipeline momentum and analyst commentary as reasons for the relative strength. Why the Market Dipped But Pfizer (PFE) Gained Today
• Positive Sentiment: Analyst optimism: a Guggenheim analyst publicly expects PFE shares to rise, reinforcing bullish sentiment among some institutional investors. Pfizer (NYSE:PFE) Stock Price Expected to Rise, Guggenheim Analyst Says
• Neutral Sentiment: Citi maintains a Hold on Pfizer—signal that some large sell‑side desks remain cautious despite pipeline momentum. Citi Remains a Hold on Pfizer (PFE)
• Neutral Sentiment: Broader industry context: oncology is undergoing rapid innovation (immunotherapy, targeted drugs, AI) which is a tailwind for large oncology players but also raises R&D and competitive intensity. Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
• Neutral Sentiment: Non‑company AI/benefits funding news (unrelated to Pfizer fundamentals) — sector interest in AI persists but limited direct impact on PFE. AI-powered Benefits Platform Origin Raises $30 Million Series A+
• Negative Sentiment: Dividend safety concerns: several pieces highlight that Pfizer’s high yield (~6%+) raises questions about payout sustainability and could pressure the stock if cash flow or M&A dynamics change. Income investors may be re‑evaluating position sizing. Income Investors Face a Hard Truth About Pfizer’s Payout Safety
• Negative Sentiment: Competitive pressure: label expansions for rivals (e.g., BMY’s Opdivo) underscore intensifying competition in IO that could cap pricing/patient share in key oncology markets. Will the Recent Label Expansion of BMY’s Opdivo Boost Its IO Franchise?

Pfizer Price Performance

Shares of Pfizer stock opened at $27.54 on Friday. The firm has a market cap of $156.59 billion, a PE ratio of 20.25 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average price of $26.82 and a 200 day moving average price of $25.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.63 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.